A Study Evaluating TRIV-509 in Atopic Dermatitis

Condition(s) studied

Investigational drug(s) / intervention(s)

TRIV-509: TRIV-509 (Subcutaneous injection)

Placebo: Drug: Placebo (Matching Placebo subcutaneous injection)

Study summary

The goal of this interventional study is to learn if TRIV-509 works to treat moderate to severe atopic dermatitis in adults. It will also evaluate the safety of TRIV-509.

Participants will receive 4 doses of the study intervention that they are randomized to (TRIV-509 or placebo), and at Week 16 will cross over and receive 4 doses of the other study intervention.

The study duration for individual participants is up to 57 weeks, including a Screening period of up to 30 days.

Eligibility

Primary outcome measure(s)

• Percentage of participants with improvement of AD at Week 16 — Baseline to Week 16

Trial sites (32)

Other trials for the same condition